| Primary |
| Pneumocystis Jiroveci Pneumonia |
22.4% |
| Prophylaxis |
12.2% |
| Product Used For Unknown Indication |
9.2% |
| Immunosuppression |
8.2% |
| Urinary Tract Infection |
6.1% |
| Cellulitis |
5.1% |
| Antifungal Prophylaxis |
3.1% |
| Clostridium Test Positive |
3.1% |
| Eosinophilic Pneumonia |
3.1% |
| Pneumocystis Jiroveci Infection |
3.1% |
| Pneumonia |
3.1% |
| Scrub Typhus |
3.1% |
| Sinusitis |
3.1% |
| Staphylococcal Infection |
3.1% |
| Acinetobacter Infection |
2.0% |
| Acne |
2.0% |
| Anaphylactic Reaction |
2.0% |
| Chronic Graft Versus Host Disease |
2.0% |
| Cystitis |
2.0% |
| Drug Therapy |
2.0% |
|
| Drug Hypersensitivity |
8.8% |
| Toxic Epidermal Necrolysis |
8.8% |
| Acute Psychosis |
7.0% |
| Drug Interaction |
7.0% |
| Rash |
7.0% |
| Renal Failure Acute |
7.0% |
| Stevens-johnson Syndrome |
7.0% |
| Anaphylactic Reaction |
5.3% |
| Blood Potassium Increased |
3.5% |
| Hyperkalaemia |
3.5% |
| Hypersensitivity |
3.5% |
| Hyponatraemia |
3.5% |
| Local Swelling |
3.5% |
| Madarosis |
3.5% |
| Respiratory Failure |
3.5% |
| Thrombocytopenia |
3.5% |
| Treatment Failure |
3.5% |
| Tremor |
3.5% |
| Vomiting |
3.5% |
| White Blood Cell Count Decreased |
3.5% |
|
| Secondary |
| Product Used For Unknown Indication |
34.4% |
| Drug Use For Unknown Indication |
10.0% |
| Hiv Infection |
7.2% |
| Burkitt's Lymphoma |
6.2% |
| Prophylaxis |
6.1% |
| Antifungal Prophylaxis |
5.5% |
| Immunosuppressant Drug Therapy |
4.9% |
| Drug Exposure During Pregnancy |
4.7% |
| Immunosuppression |
4.1% |
| Antibiotic Therapy |
2.4% |
| B Precursor Type Acute Leukaemia |
2.4% |
| Escherichia Infection |
1.8% |
| Prurigo |
1.7% |
| Acquired Immunodeficiency Syndrome |
1.6% |
| Prophylaxis Against Transplant Rejection |
1.4% |
| Urinary Tract Infection |
1.4% |
| Pneumocystis Jiroveci Pneumonia |
1.3% |
| Acute Lymphocytic Leukaemia |
1.0% |
| Bone Marrow Conditioning Regimen |
1.0% |
| Bronchopulmonary Aspergillosis |
1.0% |
|
| Vomiting |
14.1% |
| Tubulointerstitial Nephritis |
10.9% |
| Drug Rash With Eosinophilia And Systemic Symptoms |
9.8% |
| Neural Tube Defect |
6.5% |
| Respiratory Failure |
5.4% |
| Pancreatitis Haemorrhagic |
4.3% |
| Renal Failure Acute |
4.3% |
| Renal Impairment |
4.3% |
| Weight Decreased |
4.3% |
| Arthritis Bacterial |
3.3% |
| Cardiomyopathy |
3.3% |
| Completed Suicide |
3.3% |
| Convulsion |
3.3% |
| Drug Interaction |
3.3% |
| Live Birth |
3.3% |
| Multi-organ Failure |
3.3% |
| Neutropenia |
3.3% |
| Pancreatitis |
3.3% |
| Pyrexia |
3.3% |
| Serotonin Syndrome |
3.3% |
|
| Concomitant |
| Prophylaxis Against Graft Versus Host Disease |
10.6% |
| Prophylaxis |
9.1% |
| Antifungal Prophylaxis |
9.1% |
| Product Used For Unknown Indication |
8.7% |
| Hiv Infection |
8.1% |
| Infection Prophylaxis |
7.1% |
| Bone Marrow Conditioning Regimen |
6.1% |
| Drug Use For Unknown Indication |
6.0% |
| Premedication |
5.8% |
| Diffuse Large B-cell Lymphoma |
4.0% |
| Antibiotic Prophylaxis |
3.9% |
| Antiviral Prophylaxis |
3.8% |
| Stem Cell Transplant |
3.2% |
| B-cell Lymphoma |
3.0% |
| Immunosuppression |
2.4% |
| Renal Transplant |
1.9% |
| Acute Lymphocytic Leukaemia |
1.9% |
| Multiple Myeloma |
1.9% |
| Surgical Preconditioning |
1.8% |
| Peripheral T-cell Lymphoma Unspecified |
1.6% |
|
| Graft Versus Host Disease |
10.3% |
| Infection |
7.1% |
| Sepsis |
7.1% |
| Pyrexia |
6.7% |
| Transplant Failure |
6.3% |
| Thrombocytopenia |
6.0% |
| Febrile Neutropenia |
5.6% |
| Vomiting |
5.6% |
| Syncope |
5.2% |
| Weight Decreased |
5.2% |
| Pneumonia |
4.4% |
| Cytomegalovirus Infection |
3.6% |
| Lymphopenia |
3.6% |
| Renal Failure |
3.6% |
| Septic Shock |
3.6% |
| Transplant Rejection |
3.6% |
| Leukopenia |
3.2% |
| Mucosal Inflammation |
3.2% |
| Neoplasm Malignant |
3.2% |
| Neutropenia |
3.2% |
|
| Interacting |
| Interstitial Lung Disease |
42.9% |
| Arthralgia |
28.6% |
| Urinary Tract Infection |
28.6% |
|
| Asthenia |
33.3% |
| Electrocardiogram Qt Prolonged |
33.3% |
| Hyperkalaemia |
33.3% |
|
